Immunomax, lyophilizate 200 units 3 pcs

Pharmacotherapeutic group: immunomodulatory agent

Pharmacological properties

.Pharmacodynamics

Immunomax enhances immune protection against viral and bacterial infections.

The immunopharmacological mechanisms of action of the drug are that

Immunomax activates the following links of the immune system:

• NK cells, which, 2-3 hours after exposure to Immunomax, are enhanced

express CD69 activation molecules. The cytolytic activity of NK cells

increases 3-fold;

• circulating monocytes 2-4 hours after activation by Immunomax

start secreting cytokines: interleukin-8, interleukin-1b, and necrosis factor

tumor alpha;

• neutrophil granulocytes are activated through monocytes,

the drug has no direct effect on neutrophil granulocytes.

The monocyte-secreted interleukin-8 causes activation of neutrophilic

Granulocytes, which is clearly seen 24 hours after exposure

Immunomax;

• tissue macrophages, which is manifested by changes in the morphology of these cells,

increased production of bactericidal substances, changes in the activity

5′-nucleotidase;

• formation of antibodies against foreign antigens, soluble and corpuscular;

Immunomax enhances protection against infections caused by viruses (human papilloma virus

Human papillomavirus, herpes simplex virus, parvovirus, flesh-eating plague virus, etc.) or

bacteria (E. coli, salmonella, staphylococcus, chlamydia, mycoplasma,

reaplasma, etc.). This effect of the drug is manifested in adults and newborns when

Immunomax is administered in different ways: intramuscularly, intravenously,

intraperitoneally, per os.

Pharmacokinetics of the drug has not been studied due to its peptidoglycan nature and

very low potent doses.

Indications

correction of weakened immunity;
treatment of pathological conditions (condylomas, warts, dysplasia, etc.) caused by

human papillomavirus;

treatment of infections caused by herpes simplex virus, chlamydia, mycoplasma,
ureaplasma, other bacteria and viruses.

Pharmacological effect

Pharmacotherapeutic group: immunomodulatory agent

Pharmacological properties

Pharmacodynamics

Immunomax enhances immune defense against viral and bacterial infections.

The immunopharmacological mechanisms of action of the drug are that

Immunomax activates the following parts of the immune system:

NK cells, which 2-3 hours after exposure to Immunomax are intensely

express CD69 activation molecules. Cytolytic activity of NK cells

increases 3 times;

circulating monocytes 2-4 hours after activation by Immunomax

begin to secrete cytokines: interleukin-8, interleukin-1 and necrosis factor

alpha tumors;

neutrophil granulocytes are activated by monocytes,

The drug does not have a direct effect on neutrophil granulocytes.

Interleukin-8 secreted by monocytes causes activation of neutrophils

granulocytes, which clearly appears 24 hours after exposure

Immunomax;

tissue macrophages, which manifests itself in changes in the morphology of these cells,

increased production of bactericidal substances, changes in activity

5’-nucleotidases;

formation of antibodies against foreign antigens, soluble and corpuscular;

Immunomax enhances protection against infections caused by viruses (papillomavirus

human, herpes simplex virus, parvovirus, canine distemper virus, etc.) or

bacteria (Escherichia coli, salmonella, staphylococcus, chlamydia, mycoplasma,

ureaplasma, etc.). This effect of the drug occurs in adults and newborns when

administration of Immunomax in various ways: intramuscular, intravenous,

intraperitoneal, per os.

The pharmacokinetics of the drug has not been studied due to its peptidoglycan nature and

very small effective doses.

Special instructions

Information about the possible effect on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles, drive machinery or engage in other potentially hazardous activities
requiring increased concentration and speed of psychomotor reactions.

Active ingredient

Peptidoglycan acidic from potato sprouts

Composition

Immunomaxa 100 units; 200 units.
Sodium chloride 8.1 mg; 7.2 mg.

Pregnancy

Use is possible only if the potential benefit to the pregnant woman exceeds
possible harm to the fetus. Immunomax is not recommended for use by nursing mothers
mothers. Features of the use of the drug by children and adults,
those with chronic diseases, no.

Contraindications

Individual hypersensitivity to Immunomax. Children’s age up to 12 years.

Side Effects

Not found.

Interaction

Not described.

Overdose

Overdose symptoms are not described.

Storage conditions

Store at temperatures from 2° C to 8° C. Keep out of the reach of children.

Shelf life

2 years. Do not use after expiration date.

Manufacturer

Immapharma, Russia